PR Newswire
11 Apr 2023, 16:30 GMT+10
![]() |
SINGAPORE, April 11, 2023 /PRNewswire/ -- ACM Biolabs (FR0012596468 - ALSEN) a pioneering Singaporean-Swiss biotechnology company, which specializes in the development of targeted therapeutics for the prevention of multiple life-threatening diseases based on its proprietary ACM (Artificial Cell Membranes) tunable polymer-based delivery ATP technology, announces the appointment of David Lawrence as Non-Executive Director.
Mr Lawrence is currently Chief Financial Officer (CFO) of Sensorion, a gene therapy company listed on Euronext Growth in Paris and is a Director at EnteroBiotix Ltd. He was previously CFO of Valneva, a specialty vaccine company, where he served as a member of the Management Board; his responsibilities included Investor Relations and Communications in addition to overseeing the financial management of the company. During his tenure at Valneva he was instrumental in several financings including a NASDAQ Initial Public Offering (IPO) and by the point of his retirement from Valneva the market capitalisation of the company had grown to over 2bn. He also previously served as CFO of Acambis and as VP of Finance, Business Development and Strategy at Chiron Vaccines. In 2011 he supported the establishment and development of Synpromics Ltd, a synthetic promoter company that was acquired by AskBio in 2019, which was in turn acquired by Bayer in 2020.
Mr Lawrence has over 30 years' experience of leadership roles in life sciences, ranging from large biopharma companies such as GSK to start-ups and earlier stage companies, including Synpromics Ltd. He brings with him extensive industry experience including strategy, business development and M&A, and currently sits on the Boards of Enterobiotix Limited. He has also advised several life sciences Venture Capital firms between 2006 and 2017.
Madhavan Nallani, Chief Executive Officer of ACM Biolabs, commented: "We are delighted to welcome David to the team at this critical point in the development of our ATP technology. David brings a wealth of experience in strategic partnering as well as years of operational leadership in biopharma companies. I look forward to working closely with him as we progress with our partnering and accelerate the growth of ACM Biolabs."
David Lawrence said: "I am thrilled to be joining ACM at this exciting time in their development, to expand the possibilities of their novel polymer-based platform. There is huge potential in the variety of clinical areas this could be applied to. I look forward to working with Madhavan, the Board and the team to help unlock the potential of ACM and their unique technology."
About ACM Biolabs
ACM Biolabs is a pioneering Singaporean-Swiss biotechnology company with a versatile clinical platform for disease prevention and therapeutics based on its proprietary ACM (Artificial Cell Membranes) polymer-based delivery technology. ACM Biolabs' Tunable Platform (ATP), offers flexibility to deliver multiple payloads (proteins to RNA) and can successfully target specific organs. Current R&D efforts focus on the development of vaccines for infectious diseases and personalised cancer therapeutics.
ACM Biolabs' lead program, ACM-001 an adjuvanted SARS-CoV-2 spike protein (beta variant) intranasal vaccine, has demonstrated pre-clinical efficacy and safety, with the potential to disrupt viral transmission and mutation. Its phase 1 clinical trial has progressed with no adverse safety signals in cohorts 1-6 and full immunogenicity data expected in the coming weeks. The ACM-001 program also validates the clinical efficacy of the ACM polymer-based platform, enabling a wider range of clinical applications.
ACM Biolabs leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners, to leverage ATP for the formulation and targeted delivery of novel pipeline candidates.
Get a daily dose of Asia Pacific Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Asia Pacific Star.
More InformationBEIJING, China: China's national soccer team may struggle to stir excitement, but its humanoid robots are drawing cheers — and not...
]LONDON, U.K.: A World Health Organization (WHO) expert group investigating the origins of the COVID-19 pandemic released its final...
FRANKFURT, Germany: Germany has become the latest country to challenge Chinese AI firm DeepSeek over its data practices, as pressure...
BANGKOK, Thailand: This week, Thailand implemented land border restrictions, including a ban on tourists traveling to Cambodia, as...
Aluminum, copper and nickel shipments have surged this year, according to trade data Beijing has increased purchases of Russian metals...
New Delhi [India], July 1 (ANI): The Ministry of External Affairs on Tuesday announced the appointment of Jayant Khobragade of the...
NEW YORK, New York - Global stock indices closed with divergent performances on Tuesday, as investors weighed corporate earnings, central...
TORONTO, Canada: Canadian Prime Minister Mark Carney announced late on June 29 that trade negotiations with the U.S. have recommenced...
Vancouver, Canada: A high-stakes legal showdown is brewing in the world of athleisure. Lululemon, the Canadian brand known for its...
LONDON, U.K.: British oil giant Shell has denied reports that it is in talks to acquire rival oil company BP. The Wall Street Journal...
NEW YORK, New York - U.S. stock markets closed firmly in positive territory to start the week Monday, with the S&P 500 and Dow Jones...
WASHINGTON, D.C.: On Friday, President Donald Trump announced that he was halting trade discussions with Canada due to its decision...